Program
Avapritinib
Also written as “avapritinib” and “CS3007 (BLU-285)”.
Its studies are mostly in Gastrointestinal Stromal Tumors · Mastocytosis, Systemic · Leukemia, Mast-Cell · Central Nervous System Neoplasms, led by 2 companies.
Drug pageAvapritinib: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 92 open or running | phase 4since Mar 29, 2021 | Jul 23, 2015 | Jun 23, 2027phase 2 · NCT03731260 |
| CStone Pharmaceuticals | 10 open or running | phase 2since Dec 9, 2019 | Dec 9, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of CStone Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2017Named avapritinibINNProposed as its International Nonproprietary Name in WHO's List 117
- Dec 9, 2019First study: phase 2 study in Gastrointestinal Stromal TumorsFirst studyNCT04254939 · 65 enrolled · China
TargetBeta
“An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR), ”NCIt, by rule
“Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| regorafenibrule | Bayer | phase 4 | 40 |
| masitinibrule | AB Science | phase 3 | 38 |
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| ripretinibrule | Ono Pharmaceutical | phase 3 | 9 |
| seralutinibrule | gb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-inc | phase 3 | 8 |
Studies
The one study CStone Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04254939Gastrointestinal Stromal Tumors · China | 2 | Completed | Apr 30, 2020 | 65 |
How it is read
Names in the registry
- “Avapritinib”, 7 entries
- “avapritinib”, 2 entries
- “CS3007 (BLU-285)”, 1 entry
Conditions, from the studies’ own filings
- Gastrointestinal Stromal Tumors, 5 studies
- Mastocytosis, Systemic, 2 studies
- Leukemia, Mast-Cell, 2 studies
- Central Nervous System Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.